PRFX

PainReform Ltd. [PRFX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PRFX Stock Summary

Top 10 Correlated ETFs

PRFX


Top 10 Correlated Stocks

PRFX


In the News

08:30 28 Mar 2024 PRFX

PainReform to Present at the Microcap Conference in Atlantic City

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

08:30 28 Mar 2024 PRFX

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

07:42 28 Mar 2024 PRFX

Why Is PainReform (PRFX) Stock Up 38% Today?

PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.

02:15 28 Mar 2024 PRFX

PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today

In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.

09:34 28 Mar 2024 PRFX

Why Is PainReform (PRFX) Stock Down 40% Today?

PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.

08:30 28 Mar 2024 PRFX

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, which is being held June 20-22, 2023.

07:54 28 Mar 2024 PRFX

Why Is PainReform (PRFX) Stock Up 48% Today?

PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the company has received a letter from The Nasdaq Stock Market.

08:00 28 Mar 2024 PRFX

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

09:25 28 Mar 2024 PRFX

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

11:58 28 Mar 2024 PRFX

PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today

PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today appeared first on InvestorPlace.

PRFX Financial details

Company Rating
Neutral
Market Cap
3.08M
Income
-9.23M
Revenue
0
Book val./share
5.17
Cash/share
5.74
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.47
Forward P/E
-0.47
PEG
0.55
P/S
51.79
P/B
0.4
P/C
0.31
P/FCF
-0.56
Quick Ratio
7.84
Current Ratio
9.81
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-7.54
EPS next Y
-3.8
EPS next Q
-2.4
EPS this Y
-13.45%
EPS next Y
-49.61%
EPS next 5Y
-125.06%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-11930.51%
-
-
-
-
SMA20
-6.09%
SMA50
-25.4%
SMA100
-19.57%
Inst Own
0.94%
Inst Trans
1.05%
ROA
-69%
ROE
-84%
ROC
-0.95%
Gross Margin
100%
Oper. Margin
-10786%
Profit Margin
-8706%
Payout
-
Shs Outstand
1.73M
Shs Float
1.36M
-
-
-
-
Target Price
-
52W Range
0.417-26.41
52W High
-
52W Low
-
RSI
39.52
Rel Volume
0.47
Avg Volume
21.83K
Volume
10.17K
Perf Week
-3.26%
Perf Month
-15.64%
Perf Quarter
-43.38%
Perf Half Y
-49.86%
-
-
-
-
Beta
0.527
-
-
Volatility
0.07%, 0.13%
Prev Close
-1.11%
Price
1.78
Change
-1.11%

PRFX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.080
Net income per share
-3.14-12.49-7.38-8.25-7.14
Operating cash flow per share
-1.05-7.88-6.68-6.06-5.1
Free cash flow per share
-1.05-7.91-6.73-6.06-5.11
Cash per share
1.6248.3316.859.556.14
Book value per share
-9.751.2318.4310.345.53
Tangible book value per share
-9.751.2318.4310.345.53
Share holders equity per share
-9.751.2318.4310.345.53
Interest debt per share
11.583.040.010.060.36
Market cap
3.91M1.45M1.31M440.31K3.6M
Enterprise value
9.14M-14.23M-15.23M-3.66M-4.35M
P/E ratio
-2.15-0.36-0.18-0.05-0.39
Price to sales ratio
0005.120
POCF ratio
-6.41-0.57-0.2-0.07-0.54
PFCF ratio
-6.41-0.56-0.2-0.07-0.54
P/B Ratio
-0.690.090.070.040.5
PTB ratio
-0.690.090.070.040.5
EV to sales
000-42.510
Enterprise value over EBITDA
-12.48.182.110.420.45
EV to operating cash flow
-15.015.562.320.570.65
EV to free cash flow
-15.015.542.310.570.65
Earnings yield
-0.47-2.8-5.55-19.97-2.6
Free cash flow yield
-0.16-1.77-5.06-14.68-1.86
Debt to equity
-1.10000.01
Debt to assets
5.30000.01
Net debt to EBITDA
-7.19.012.290.470.83
Current ratio
0.1518.5125.1311.554.07
Interest coverage
-1.27-1.69-720.8-145.39-24.96
Income quality
0.480.630.90.730.71
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00051.710
Research and developement to revenue
00051.420
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
000-0.070
Capex to depreciation
0-0.01-7.14-0.4-0.6
Stock based compensation to revenue
00016.150
Graham number
26.18120.0155.3343.829.8
ROIC
-1.78-0.11-0.4-0.81-1.3
Return on tangible assets
-1.56-0.23-0.38-0.71-0.94
Graham Net
-10.0547.9517.1512.034.11
Working capital
-5.37M16.83M18.26M11.22M7.39M
Tangible asset value
-5.62M16.62M18.08M11.02M7.24M
Net current asset value
-5.81M16.61M18.03M10.98M7.11M
Invested capital
-1.10000.01
Average receivables
25K37.5K135.5K136.5K50K
Average payables
1000360K428K172.5K215K
Average inventory
3K1.02M2.14M5.03M3.91M
Days sales outstanding
000233.430
Days payables outstanding
007.09K5.09K5.38K
Days of inventory on hand
2.19K0116.54K190.36K0
Receivables turnover
0001.560
Payables turnover
000.050.070.07
Inventory turnover
0.170000
ROE
0.32-0.24-0.4-0.8-1.29
Capex per share
0-0.03-0.05-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.080000
Net income per share
-2.96-2.05-2.030.03-3.49
Operating cash flow per share
-2.7-1.82-1.87-0.96-1.06
Free cash flow per share
-2.7-1.82-1.87-0.97-1.06
Cash per share
9.577.595.747.025.74
Book value per share
10.368.296.57.075.17
Tangible book value per share
10.368.296.57.075.17
Share holders equity per share
10.368.296.57.075.17
Interest debt per share
-0.09-0.100.080.06
Market cap
439.19K739.76K588.59K4.25M3.85M
Enterprise value
-3.66M-7.4M-4.55M-3.21M-4.1M
P/E ratio
-0.03-0.08-0.0729.52-0.2
Price to sales ratio
5.110000
POCF ratio
-0.15-0.38-0.29-3.63-2.6
PFCF ratio
-0.15-0.38-0.29-3.6-2.6
P/B Ratio
0.040.080.080.490.53
PTB ratio
0.040.080.080.490.53
EV to sales
-42.520000
Enterprise value over EBITDA
1.153.062.031.071.15
EV to operating cash flow
1.283.792.272.742.77
EV to free cash flow
1.273.792.272.722.77
Earnings yield
-7.16-2.97-3.710.01-1.27
Free cash flow yield
-6.54-2.64-3.4-0.28-0.38
Debt to equity
0000.010.01
Debt to assets
0000.010.01
Net debt to EBITDA
1.293.372.292.492.23
Current ratio
11.558.17.559.814.07
Interest coverage
32.8922.37-563-270.4-1.19K
Income quality
0.910.850.92-32.560.3
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
15.20000
Research and developement to revenue
22.660000
Intangibles to total assets
00000
Capex to operating cash flow
0000.010
Capex to revenue
-0.070000
Capex to depreciation
-100-2.67-0.16
Stock based compensation to revenue
8.560000
Graham number
26.2619.5617.252.1720.16
ROIC
-0.29-0.26-0.31-6.06-0.49
Return on tangible assets
-0.26-0.21-0.260-0.49
Graham Net
12.066.174.495.183.84
Working capital
11.22M9.1M7.18M9.65M7.39M
Tangible asset value
11.02M8.89M6.97M8.64M7.24M
Net current asset value
10.98M8.85M6.94M8.5M7.11M
Invested capital
0000.010.01
Average receivables
27.5K27.5K0022.5K
Average payables
297K261K191.5K142K217.5K
Average inventory
3.91M3.91M000
Days sales outstanding
57.560000
Days payables outstanding
3.14K14.09K1.58K6.42K3.32K
Days of inventory on hand
117.35K0000
Receivables turnover
1.560000
Payables turnover
0.030.010.060.010.03
Inventory turnover
00000
ROE
-0.29-0.25-0.310-0.68
Capex per share
-0.0100-0.010

PRFX Frequently Asked Questions

What is PainReform Ltd. stock symbol ?

PainReform Ltd. is a IL stock and trading under the symbol PRFX

What is PainReform Ltd. stock quote today ?

PainReform Ltd. stock price is $1.78 today.

Is PainReform Ltd. stock public?

Yes, PainReform Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap